Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dolcanatide - Bausch Health Companies

Drug Profile

Dolcanatide - Bausch Health Companies

Alternative Names: SP 333

Latest Information Update: 11 Mar 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Synergy Pharmaceuticals Inc
  • Developer National Cancer Institute (USA); Synergy Pharmaceuticals Inc
  • Class Anti-inflammatories; Peptide hormones
  • Mechanism of Action Guanylate cyclase C agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Constipation
  • Phase I Colorectal cancer; Ulcerative colitis

Most Recent Events

  • 06 Mar 2019 Bausch Health acquires dolcanatide and related intellectual property from Synergy Pharmaceuticals
  • 12 Dec 2018 Bausch Health plans to acquire intellectual property, plecanatide and dolcanatide from Synergy Pharmaceuticals
  • 27 Jul 2018 Phase-I clinical trials in Colorectal cancer (Prevention) in USA (PO) (NCT03300570)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top